BCDA Stock Analysis: Buy, Sell, or Hold?
BCDA - BioCardia, Inc. Common Stock
$0.89
-0.07 (-7.54%)
▼
5d:
-25.01%
30d:
-3.0%
90d:
-26.25%
WAIT
LOW Confidence
Analysis Updated: Jul 9, 2026 12:00 AM ET
Earnings: Aug 10, 2026
30d
Get Alerted When BCDA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: BCDA is down 25.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: BCDA is down 25.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: BCDA is currently trading at $0.89, which is considered slightly high relative to its 30-day fair value range of $0.86 to $1.13.
Technical Outlook: Technically, BCDA is in a downtrend. The price is currently testing key support at $0.89. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.5% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $15.50 (+1636.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BCDA is in a downtrend. The price is currently testing key support at $0.89. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.5% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $15.50 (+1636.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$0.86 -
$1.13
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
61.6%
All Signals
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-7.5%)
- BULLISH: Trading 1636.9% below Wall St target ($15.50)
- WARNING: Recommendation downgraded due to -25.0% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$0.86 -
$1.13
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$0.89
Resistance Level
$1.26
Current Trend
Downtrend
Technical data as of
Jul 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.49
Wall Street Target
$15.50
(+1636.9%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: July 10, 2026 8:40 AM ET
Data refreshes hourly during market hours. Next update: 9:40 AM
Data refreshes hourly during market hours. Next update: 9:40 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BCDA showing a specific setup today?
Insider Activity (6 Months)
5
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Peter Altman
BUY
400 shares
2026-04-21
Peter Altman
BUY
600 shares
2026-04-20
Peter Altman
BUY
5000 shares
2026-02-04
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 55 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$108 | 63 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 56 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$106 | 43 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$111 | 62 BUY |